Home » Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
Pfizer is trumpeting its exclusive rights to one of its best-selling products until late 2018 after a Delaware district court upheld its patents on pain and seizure drug Lyrica. A Wilmington, Del., federal judge ruled Teva Pharmaceuticals and other generic-drug applicants would infringe on Lyrica’s (pregabalin) patents and enjoined them from making or selling their products until then.
Generic Line
Generic Line
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May